Precision Medicine for Nociception, Sngception and Proprioception.
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Precision medicine is defined as "an emerging approach for disease treatment and prevention
that takes into account individual variability in genes, environment, and lifestyle for each
person" by the Precision Medicine Initiative.
Patients have different response to different treatment modalities, and sore/pain medicine is
no exception. In our experience, low-level laser (LLL), ultrasound, and prolotherapy can
reduce sore /pain through different genetic pathway. Whether the therapeutic effect is
controlled by the genetic variants of those sore /pain related genes or not, is still in
debate. The aims of this study are (1) To set up next generation sequencing (NGS)-based
approach to find genetic variants which can determine the response of sng/pain treatment
modalities and the phenotype of idiopathic scoliosis. (2) To find possible metabolomics and
proteomic markers of sng/pain. (3) To determine the algorithm of precision medicine for
sng/pain control via the genetic markers.
Investigators will recruit 80 myofascial pain participant and 80 idiopathic scoliosis
participant from Department of Physical Medicine and Rehabilitation, National Taiwan
University Hospital Bei-Hu Branch in 2023 and 2025. The myofascial pain participant
participants will receive LLL, ultrasound, and prolotherapy, and the therapeutic effect will
be recorded. The clinical trial will evaluate the Sng / pain (VAS) and muscle tone of the
idiopathic scoliosis participant. The blood and urine samples from the first, the second, and
the third visits will be analyzed by next generation sequencing, and mass spectrometry to
find the possible biomarker in 2024 and 2025. Investigators expect to develop the
individualized treatment plan by means of these biomarkers. Hopefully, the results will be
widely applied in the field of sore /pain medicine.
Phase:
N/A
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
National Health Research Institutes, Taiwan National Science and Technology Council